AHOD1721, Risk-based, Response-Adapted, Phase ll Open- Label Trail of Nivolumab+Brentuximab Vedotin(N+Bv) for Children,Adolescents, and Young Adults with Relapsed/ Refractory (R/R) CD30+ Classic Hodgkin Lymphoma (cHL) after Failure of First -Line Therapy, followed by Brentuximab+Bendamustine(Bv+B) for participants with a suboptimal response;CheckMate 744:Checkpoint Pathway and Nivolumab Clinical Trail Evaluation.

Grant

Date/time Interval

  • October 19, 2017 - October 18, 2022
  • Total Award Amount

  • 49200.00
  • Direct Costs

  • 37846.00
  • Sponsor Award Id

  • Contributor

  • Aman Wadhwa   Investigator  
  • Ana Galtarossa Xavier   Principal Investigator  
  • Jeanine Dumas   Investigator  
  • Julie Wolfson-Stockman M.D.   Investigator  
  • Matthew Kutny M.D.   Investigator  
  • Wayne Liang   Investigator